ストックスクリーナーアプリを入手
2.36
4.07%
-0.10
アフターアワーズ：
2.36
Editas Medicine Inc (EDIT) 最新ニュース
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc - GuruFocus
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medici - GuruFocus
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com - Investing.com South Africa
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock By Investing.com - Investing.com South Africa
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock - Investing.com
Editas Medicine CFO Amy Parison sells $1,253 in stock - Investing.com
Editas Medicine (EDIT) CFO logs small automatic tax-related share sale - Stock Titan
Editas Medicine (EDIT) CEO logs automatic, tax-related share sale - Stock Titan
Editas Medicine (EDIT) CSO sells 731 shares under automatic tax-cover plan - Stock Titan
EDIT: EDIT-401 shows durable 90% LDL and Lp(a) reduction, with clinical trials starting in 2024 - TradingView
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? - Yahoo Finance
RA Capital affiliates report 8.89M shares in Editas Medicine (EDIT) - Stock Titan
TCG Crossover group reports 9.9% stake in Editas Medicine (EDIT) after offering - Stock Titan
Commodore reports 16.05M-share position in Editas Medicine (EDIT) under 9.99% cap - Stock Titan
Editas Medicine Inc stock (US28106W1036): Q1 2026 loss narrows as Nasdaq-listed gene-editing player - AD HOC NEWS
Genome Editing Market to Reach $13.36 Billion by 2035, Growing - openPR.com
Editas Medicine Q1 2026 Earnings: Narrowing Losses on Reduced Expenses as CRISPR Pipeline AdvancesEBITDA Analysis - newsline.com
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - The Motley Fool
Editas Medicine Inc stock (US28106W1036): Nasdaq gene-editing share trades quietly ahead of next cat - AD HOC NEWS
EDIT (NASDAQ) insider notice: 15,000-share resale; 32,957 RSUs vested - Stock Titan
Cardiovascular in-licensing play Kardigan looking for quick path to IPO: Finance Report - biocentury.com
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference - Caledonian Record
Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT) - Seeking Alpha
Q2 EPS Estimates for Editas Medicine Raised by HC Wainwright - MarketBeat
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX - RTTNews
Analysts Issue Forecasts for Editas Medicine Q2 Earnings - MarketBeat
Editas Medicine (EDIT) Unveils Promising Data for EDIT-401 - GuruFocus
Editas Medicine (EDIT) Showcases Promising Preclinical Findings - GuruFocus
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Editas Medicine stock dips on proposed equity offering - MSN
Editas Medicine Announces $319.4 Million Public Offering with CRISPR Gene Editing Focus - Minichart
HC Wainwright Weighs in on Editas Medicine Q3 Earnings - MarketBeat
Editas Medicine (NASDAQ: EDIT) sells 55.6M shares with warrants to fund EDIT-401 - Stock Titan
Editas Medicine (NASDAQ: EDIT) prices equity deal, extends cash runway to 2H 2028 - Stock Titan
Editas Medicine Prices Public Offering of Shares, Warrants - Moomoo
Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell - Moomoo
H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Editas Medicine (EDIT) Initiates Public Offering of Common Stock - GuruFocus
Editas Medicine (EDIT) Shares Drop Following Stock Offering Anno - GuruFocus
EDIT: Financing Efforts Advance with Recent Offering - GuruFocus
Editas Medicine prices $125M stock offering with warrants - Investing.com UK
Editas Medicine prices $125M stock offering with warrants By Investing.com - Investing.com Nigeria
Editas Medicine stock tumbles on stock offering announcement By Investing.com - Investing.com Australia
Editas reports preclinical data for gene editing treatment - Investing.com UK
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):